002390 信邦制药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入4,266,285-6.55%6,032,2626,460,8416,350,0266,471,866
减:营业总成本4,026,406-5.86%5,712,4736,029,9576,015,5746,003,799
    其中:营业成本3,522,176-5.42%4,996,3685,232,2655,133,0655,119,371
               财务费用11,106-15.84%16,60327,75338,97987,166
               资产减值损失----(3,986)(7,523)----
公允价值变动收益------------
投资收益266-79.53%2,9279,39737,4273,920
    其中:对联营企业和合营企业的投资收益----------47
营业利润235,402-11.92%254,847385,033316,323451,510
利润总额225,227-14.77%185,501396,022313,394421,125
减:所得税费用24,450-22.47%29,81142,24945,13847,170
净利润200,777-13.73%155,690353,773268,255373,955
减:非控股权益48,452-13.71%54,30866,54043,881101,086
股东净利润152,325-13.74%101,382287,233224,374272,869

市场价值指针
每股收益 (元) *0.080-13.38%0.0500.1500.1200.150
每股派息 (元) *0.0300.00%0.0600.0600.0600.060
每股净资产 (元) *3.472-0.53%3.4523.5253.5033.265
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容